BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18755702)

  • 1. The immunodeficiency of chronic lymphocytic leukaemia.
    Hamblin AD; Hamblin TJ
    Br Med Bull; 2008; 87():49-62. PubMed ID: 18755702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immune globulin in chronic lymphocytic leukaemia.
    Gamm H; Huber C; Chapel H; Lee M; Ries F; Dicato MA
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):17-20. PubMed ID: 8033428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine- and immune-based therapy in chronic lymphocytic leukemia.
    Le Dieu R; Gribben J
    Semin Oncol; 2006 Apr; 33(2):220-9. PubMed ID: 16616069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infection and immunity in chronic lymphocytic leukemia.
    Tsiodras S; Samonis G; Keating MJ; Kontoyiannis DP
    Mayo Clin Proc; 2000 Oct; 75(10):1039-54. PubMed ID: 11040852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
    Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairments in immune cell function in B cell chronic lymphocytic leukemia.
    Bartik MM; Welker D; Kay NE
    Semin Oncol; 1998 Feb; 25(1):27-33. PubMed ID: 9482524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?
    Molica S
    Haematologica; 1997; 82(6):705-9. PubMed ID: 9499672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoglobulin replacement in chronic lymphocytic leukaemia.
    Bunch C
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):419-22. PubMed ID: 3065737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary immunodeficiency in lymphoproliferative malignancies.
    Friman V; Winqvist O; Blimark C; Langerbeins P; Chapel H; Dhalla F
    Hematol Oncol; 2016 Sep; 34(3):121-32. PubMed ID: 27402426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.
    Morrison VA
    Best Pract Res Clin Haematol; 2010 Mar; 23(1):145-53. PubMed ID: 20620978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypogammaglobulinaemia associated with abnormalities of both B and T lymphocytes in patients with chronic lymphatic leukaemia.
    Hersey P; Wotherspoon J; Reid G; Gunz FW
    Clin Exp Immunol; 1980 Mar; 39(3):698-707. PubMed ID: 6445798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia.
    Pritsch O; Maloum K; Dighiero G
    Semin Oncol; 1998 Feb; 25(1):34-41. PubMed ID: 9482525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera.
    Shimoni A; Marcus H; Dekel B; Shkarchi R; Arditti F; Shvidel L; Shtalrid M; Bucher W; Canaan A; Ergas D; Berrebi A; Reisner Y
    Cancer Res; 1999 Dec; 59(23):5968-74. PubMed ID: 10606243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia.
    Tabarkiewicz J; Giannopoulos K
    Transplant Proc; 2010 Oct; 42(8):3293-6. PubMed ID: 20970674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoglobulins--merely expensive or also useful?].
    Paar WD
    Ther Umsch; 1995 Oct; 52(10):639-44. PubMed ID: 7482374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages.
    Hus I; Kawiak J; Tabarkiewicz J; Radej S; Hoser G; Bojarska-Junak A; Schmitt M; Giannopoulos K; Dmoszynska A; Rolinski J
    Oncol Rep; 2008 Aug; 20(2):443-51. PubMed ID: 18636210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.